SMAD1-AS2: A Potential Drug Target and Biomarker (G101927659)

Target Name: SMAD1-AS2

NCBI ID: G101927659

SMAD1-AS2

Other Name(s): SMAD1 antisense RNA 2

SMAD1-AS2: A Potential Drug Target and Biomarker

SMAD1-AS2 (SMAD1 antisense RNA 2) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to investigate, and its potential as a drug may have significant implications for the treatment of certain diseases.

SMAD1-AS2 is a RNA molecule that is derived from the SMAD family of proteins, which are known for their role in regulating gene expression. SMAD1-AS2 is composed of a stem-loop region and a terminal exon, which is similar to other RNA molecules known as microRNAs. The stem-loop region of SMAD1-AS2 contains a unique sequence that is specific to the SMAD1 gene, and this sequence has been shown to have various functions in different organisms.

One of the unique features of SMAD1-AS2 is its ability to interact with the SMAD2 protein, which is a well-known protein that is involved in various cellular processes. This interaction between SMAD1-AS2 and SMAD2 has been shown to play a role in the regulation of gene expression and in the development of certain diseases.

SMAD1-AS2 has also been shown to be involved in the regulation of cell cycle progression, and this role may be relevant to the treatment of certain types of cancer. The SMAD1-AS2 protein has been shown to inhibit the activity of the transcription factor, p21, which is involved in the regulation of cell cycle progression. This inhibition of p21 may have the potential to slow down the growth and spread of certain types of cancer cells.

In addition to its potential role in cancer treatment, SMAD1-AS2 may also be a useful biomarker for the disease. The presence of the SMAD1-AS2 protein in certain types of cancer has been shown to be associated with a poor prognosis, but the exact mechanisms by which this is accomplished are not yet fully understood. As a potential drug target, the study of SMAD1-AS2 may provide insights into the mechanisms of cancer development and progression, and may lead to the development of new, more effective treatments for this disease.

In conclusion, SMAD1-AS2 is a promising drug target and biomarker for the treatment of various diseases, including cancer. Its unique structure and function, as well as its potential as a drug, make it an attractive target for researchers to investigate further. Further studies are needed to fully understand the role of SMAD1-AS2 in the regulation of gene expression and cell cycle progression, as well as its potential as a biomarker for cancer.

Protein Name: SMAD1 Antisense RNA 2

The "SMAD1-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMAD1-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets